Edition:
United States

Laboratory Corporation of America Holdings (LH.N)

LH.N on New York Stock Exchange

165.17USD
20 Apr 2018
Change (% chg)

$-3.09 (-1.84%)
Prev Close
$168.26
Open
$167.98
Day's High
$168.34
Day's Low
$164.55
Volume
294,436
Avg. Vol
177,985
52-wk High
$181.65
52-wk Low
$134.49

Latest Key Developments (Source: Significant Developments)

LabCorp Says CEO David King's FY 2017 Total Compensation Was $11.6 Mln
Friday, 30 Mar 2018 04:55pm EDT 

March 30 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP SAYS CEO DAVID KING'S FY 2017 TOTAL COMPENSATION WAS $11.6 MILLION INCLUDING $6.7 MILLION OF STOCK AWARDS - SEC FILING.  Full Article

Laboratory Corp Says Co, Appalachian Regional Healthcare Entered Multi-Year, Comprehensive Laboratory Partnership‍​
Thursday, 22 Mar 2018 09:52am EDT 

March 22 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP - CO, APPALACHIAN REGIONAL HEALTHCARE ENTERED MULTI-YEAR, COMPREHENSIVE LABORATORY PARTNERSHIP‍​.  Full Article

Interpace Diagnostics Announces Expansion Of Labcorp National Agreement
Tuesday, 20 Mar 2018 08:00am EDT 

March 20 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS ANNOUNCES EXPANSION OF LABCORP NATIONAL AGREEMENT.INTERPACE DIAGNOSTICS - AGREEMENT WITH LABCORP TO FURTHER EXPAND CO'S NETWORK OF CYTOLOGY PROVIDERS IN SUPPORT OF ITS THYROID MOLECULAR BUSINESS UNIT​.INTERPACE DIAGNOSTICS - ‍ UNDER NEW AGREEMENT, PHYSICIANS WILL BE ABLE TO ORDER BOTH THYROID BIOPSY ANALYSIS AND MOLECULAR TESTING FROM INTERPACE​.  Full Article

Covance Forms Immunology & Immunotoxicology Unit Focused On Biologic Drug Development
Friday, 9 Mar 2018 08:45am EST 

March 9 (Reuters) - Laboratory Corporation Of America Holdings ::COVANCE FORMS IMMUNOLOGY & IMMUNOTOXICOLOGY UNIT FOCUSED ON BIOLOGIC DRUG DEVELOPMENT.LABCORP - COVANCE DRUG DEVELOPMENT BUSINESS HAS FORMED A GLOBAL IMMUNOLOGY AND IMMUNOTOXICOLOGY UNIT.  Full Article

Labcorp Says On Track To Deliver $150 Mln In Cumulative New Revenue From Covance Acquisition Through 2018‍​
Tuesday, 6 Mar 2018 08:25am EST 

March 6 (Reuters) - Laboratory Corporation Of America Holdings LH.N::LABCORP - ON TRACK TO DELIVER $150 MILLION IN CUMULATIVE NEW REVENUE FROM COVANCE ACQUISITION THROUGH 2018 - SEC FILING‍​.  Full Article

LabCorp Reports Q4 Earnings Per Share $6.81
Tuesday, 6 Feb 2018 06:57am EST 

Feb 6 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP ANNOUNCES RECORD 2017 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2018 GUIDANCE.Q4 EARNINGS PER SHARE $6.81.Q4 REVENUE ROSE 13.2 PERCENT TO $2.7 BILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.30 TO $11.70.Q4 ADJUSTED EARNINGS PER SHARE $2.45.LABCORP SEES 2018 FREE CASH FLOW OF $1.1 BILLION TO $1.2 BILLION.Q4 EARNINGS PER SHARE VIEW $2.38, REVENUE VIEW $2.69 BILLION -- THOMSON REUTERS I/B/E/S.BACKLOG FOR COVANCE DRUG DEVELOPMENT AT END OF QUARTER WAS $7.13 BILLION.LABCORP SEES 2018 REVENUE GROWTH OF 9.5% TO 11.5% OVER 2017 RESTATED REVENUE OF $10.42 BILLION.‍DURING QUARTER, RECORDED A NET BENEFIT OF $519.0 MILLION IN NET EARNINGS, OR $5.00 PER SHARE, DUE TO IMPLEMENTATION OF TAX LAW​.EXPECTS ABOUT $2.8 BILLION OF BACKLOG IN COVANCE DRUG DEVELOPMENT TO CONVERT INTO REVENUE IN NEXT TWELVE MONTHS.FY2018 EARNINGS PER SHARE VIEW $10.79, REVENUE VIEW $11.03 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
Wednesday, 15 Nov 2017 08:45am EST 

Nov 15 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo®.Laboratory Corporation Of America Holdings - ‍announced U.S. availability of PD-L1 ihc 28-8 pharmdx assay as complementary diagnostic for 2 indications in connection with use of Opdivo​.  Full Article

Labcorp - Co,‍ Capital Health announced that they have entered into a laboratory partnership​
Wednesday, 1 Nov 2017 08:45am EDT 

Nov 1 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp - Co,‍ Capital Health announced that they have entered into a laboratory partnership​.  Full Article

LabCorp reports Q3 adjusted earnings per share of $2.46
Wednesday, 25 Oct 2017 06:55am EDT 

Oct 25 (Reuters) - Laboratory Corporation Of America Holdings :LabCorp announces record third quarter results and increases 2017 guidance.Q3 adjusted earnings per share $2.46.Q3 earnings per share $1.74.Q3 revenue $2.6 billion versus I/B/E/S view $2.55 billion.Q3 earnings per share view $2.39 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $9.40 to $9.60.LabCorp - ‍backlog for covance drug development at end of quarter was $6.84 billion, which includes backlog from Chiltern acquisition of $1.0 billion ​.LabCorp - ‍expects approximately $2.7 billion of backlog in covance drug development to convert into revenue in next twelve months​.LabCorp - ‍sees 2017 free cash flow increased to $970 million to $1,010 million, up 8% to 13% over 2016​.LabCorp sees ‍for 2017 net revenue growth of 8.0% to 8.5% over 2016 net revenue of $9.44 billion​.FY2017 earnings per share view $9.50, revenue view $10.10 billion -- Thomson Reuters I/B/E/S.LabCorp says "‍revenue growth" in quarter "was negatively impacted by approximately 0.7% due to multiple hurricanes during quarter​".  Full Article

Luminex Corp - Labcorp agrees to extend commitment to Luminex Cystic Fibrosis
Monday, 11 Sep 2017 05:13pm EDT 

Sept 12 (Reuters) - Laboratory Corporation Of America Holdings :Luminex Corp - Agreement with Labcorp whereby Labcorp agreed to extend commitment to the Luminex Cystic Fibrosis product line through December 31, 2019.  Full Article